Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Total Valuation
Karyopharm Therapeutics has a market cap or net worth of $51.67M. The enterprise value is $170.92M.
Market Cap$51.67M
Enterprise Value$170.92M
Share Statistics
Karyopharm Therapeutics has 8,569,618 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,569,618
Owned by Insiders2.44%
Owned by Institutions20.38%
Financial Efficiency
Karyopharm Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is -163.68%.
Return on Equity (ROE)0.41
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-163.68%
Return on Capital Employed (ROCE)-1.66
Revenue Per Employee520.56K
Profits Per Employee-273.91K
Employee Count279
Asset Turnover0.88
Inventory Turnover1.27
Valuation Ratios
The current PE Ratio of Karyopharm Therapeutics is -16.17. Karyopharm Therapeutics’s PEG ratio is 0.33.
PE Ratio-16.17
PS Ratio0.37
PB Ratio-6.64
Price to Fair Value-6.64
Price to FCF-9.68
Price to Operating Cash Flow-9.69
PEG Ratio0.33
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M and earned -76.42M in profits. Earnings per share was -0.63.
Revenue145.24M
Gross Profit139.23M
Operating Income-119.44M
Pretax Income-76.36M
Net Income-76.42M
EBITDA-38.60M
Earnings Per Share (EPS)-0.63
Cash Flow
In the last 12 months, operating cash flow was -127.49M and capital expenditures -142.00K, giving a free cash flow of -127.63M billion.
Operating Cash Flow-127.49M
Free Cash Flow-127.63M
Free Cash Flow per Share-14.89
Dividends & Yields
Karyopharm Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-61.65%
50-Day Moving Average6.33
200-Day Moving Average10.52
Relative Strength Index (RSI)62.17
Average Volume (3m)144.38K
Important Dates
Karyopharm Therapeutics upcoming earnings date is May 1, 2025, TBA Not Confirmed.
Last Earnings DateFeb 19, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Karyopharm Therapeutics as a current ratio of 1.70, with Debt / Equity ratio of -104.57%
Current Ratio1.70
Quick Ratio1.64
Debt to Market Cap0.08
Net Debt to EBITDA-0.97
Interest Coverage Ratio-3.19
Taxes
In the past 12 months, Karyopharm Therapeutics has paid 57.00K in taxes.
Income Tax57.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Karyopharm Therapeutics EV to EBITDA ratio is -32.98, with an EV/FCF ratio of -9.98.
EV to Sales8.77
EV to EBITDA-32.98
EV to Free Cash Flow-9.98
EV to Operating Cash Flow-9.99
Balance Sheet
Karyopharm Therapeutics has $108.71M in cash and marketable securities with $0.00 in debt, giving a net cash position of $85.81M billion.
Cash & Marketable Securities$108.71M
Total Debt$0.00
Net Cash$85.81M
Net Cash Per Share$10.01
Tangible Book Value Per Share-$1.53
Margins
Gross margin is 95.74%, with operating margin of -82.24%, and net profit margin of -52.62%.
Gross Margin95.74%
Operating Margin-82.24%
Pretax Margin-52.58%
Net Profit Margin-52.62%
EBITDA Margin-26.58%
EBIT Margin-26.81%
Analyst Forecast
The average price target for Karyopharm Therapeutics is $53.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$53.67
Price Target Upside755.98% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-0.55%
EPS Growth Forecast49.85%